/ The Lancet Oncology
Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer.
Rentsch CA, Hayoz S, Cathomas R.
Lancet Oncol. 2021 Sep;22(9):e379.
/ The Lancet Oncology
Rentsch CA, Hayoz S, Cathomas R.
Lancet Oncol. 2021 Sep;22(9):e379.